Cerevel Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapies for a broad range of neuroscience diseases. Spun out from Pfizer in 2018 with foundational investment from Bain Capital, Cerevel focuses on advancing a differentiated pipeline targeting conditions such as schizophrenia, Parkinson's disease, epilepsy, and dementia-related apathy. Their approach combines a deep understanding of brain neurocircuitry with expertise in drug development to bring potentially transformative treatments to patients. In December 2023, AbbVie announced a definitive agreement to acquire Cerevel Therapeutics, aiming to enhance its neuroscience portfolio.
The Cambridge headquarters serves as the central hub for Cerevel's research and development activities, clinical operations, corporate strategy, and general administrative functions.
The facility likely includes state-of-the-art laboratory spaces, modern office layouts designed for collaboration, and is situated to leverage the dense biotech ecosystem of Kendall Square.
Cerevel's work culture is reported to be dynamic and science-driven, emphasizing innovation, collaboration among multidisciplinary teams, and a strong patient-centric focus to address significant unmet medical needs in neuroscience.
Its location in Cambridge provides strategic advantages, including access to a rich talent pool, leading academic and research institutions, and a vibrant community of biotech peers and potential partners.
Cerevel Therapeutics's primary operational footprint, including R&D and corporate functions, is centered in the United States. While direct international office locations are not prominently listed, the company's clinical development programs for its therapeutic candidates may involve trial sites and collaborations across multiple countries, managed through its US base or via contract research organizations (CROs). Its global reach is expected to expand upon successful product approvals and commercialization strategies, particularly under the pending acquisition by AbbVie.
222 Jacobs Street, Suite 200
Cambridge
Massachusetts
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cerevel Therapeutics' leadership includes:
Cerevel Therapeutics has been backed by several prominent investors over the years, including:
Over the past year, Cerevel Therapeutics has experienced key leadership adjustments, most notably the appointment of a new Chief Financial Officer. These changes come as the company continues to advance its clinical pipeline and prepares for its pending acquisition by AbbVie.
Discover the tools Cerevel Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cerevel Therapeutics likely utilizes standard corporate email address formats. The most common patterns for companies of its structure and industry are [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com].
first.last@cerevel.com
Format
jane.doe@cerevel.com
Example
85%
Success rate
Cerevel Therapeutics Investor Relations • May 9, 2024
Cerevel Therapeutics announced the appointment of Susan Altschuller, Ph.D., as its new Chief Financial Officer, effective June 3, 2024. Dr. Altschuller succeeds Mark Bodenrader, who served as interim CFO....more
AbbVie News Center • December 6, 2023
AbbVie announced a definitive agreement to acquire Cerevel Therapeutics for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This acquisition is intended to significantly strengthen AbbVie's neuroscience pipeline with Cerevel's portfolio of promising clinical and preclinical assets....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cerevel Therapeutics, are just a search away.